Publications by authors named "G Veerman"
Article Synopsis
- Alectinib is a treatment for ALK+ non-small cell lung cancer, but many patients experience drug-related toxicity requiring dose adjustments, potentially linked to genetic variants.
- In a study of 215 patients, 47% had severe toxicity, with females being more affected and having higher drug levels. Additionally, specific genetic variants like PPAR-α 209G>A were associated with increased toxicity.
- Identifying these genetic factors could help tailor treatments and reduce adverse effects, suggesting the need for pre-treatment genetic testing and possible dose modifications.
Clinical implications of nintedanib pharmacokinetics in patients with pulmonary fibrosis.
Biomed Pharmacother
October 2024
Background: Nintedanib is used to treat both idiopathic and progressive pulmonary fibrosis (IPF/PPF). Evidence of both an exposure-response relationship and an exposure-toxicity relationship has been found, suggesting the potential value of therapeutic drug monitoring (TDM). We aimed to define the therapeutic window of nintedanib in a real-world cohort.
View Article and Find Full Text PDFIntroduction: Brain metastases (BM) are common in patients with advanced -mutated (m+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic failure due to low plasma trough levels (C) and consequently limited intracranial osimertinib exposure.
View Article and Find Full Text PDFBackground: Esophagectomy for esophageal cancer has a complication rate of up to 60%. Prediction models could be helpful to preoperatively estimate which patients are at increased risk of morbidity and mortality. The objective of this study was to determine the best prediction models for morbidity and mortality after esophagectomy and to identify commonalities among the models.
View Article and Find Full Text PDF